GLMD - Galmed Pharmaceuticals Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
14.68
-0.33 (-2.20%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close15.01
Open14.84
Bid0.00 x 1200
Ask0.00 x 2900
Day's Range14.50 - 15.37
52 Week Range3.61 - 27.06
Volume747,155
Avg. Volume732,879
Market Cap306.928M
Beta3.03
PE Ratio (TTM)N/A
EPS (TTM)-0.89
Earnings DateMay 14, 2018 - May 18, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.14
Trade prices are not sourced from all markets
  • Here's Why Galmed Pharmaceuticals Ltd. Was Up 19% Today and 33% for the Week
    Motley Fool4 days ago

    Here's Why Galmed Pharmaceuticals Ltd. Was Up 19% Today and 33% for the Week

    Analysts love this biotech, but should you?

  • Benzinga5 days ago

    Galmed Notches Second Bullish Rating On Aramchol Opportunity

    Two days after Cantor Fitzgerald gave  Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) a shot in the arm with an ultrabullish rating , Stifel Nicolaus administered a booster. Galmed spiked 15 percent Friday ...

  • ACCESSWIRE5 days ago

    Today's Research Reports on Stocks to Watch: Galmed Pharmaceuticals and Zogenix

    NEW YORK, NY / ACCESSWIRE / July 13, 2018 / An analyst at Cantor Fitzgerald thinking that Galmed Pharmaceuticals is undervalued in the NASH space had traders cheering on Thursday, sending shares higher ...

  • Galmed Stock Rose Over 26% on ‘Overweight’ Rating
    Market Realist5 days ago

    Galmed Stock Rose Over 26% on ‘Overweight’ Rating

    Galmed Stock Rose Over 26% on 'Overweight' RatingGalmed Pharmaceuticals coverage initiated by Cantor Fitzgerald

  • Benzinga6 days ago

    Cantor Fitzgerald Makes An Uber-Bullish Call On Galmed Pharmaceuticals

    Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) earned another bullish analyst this week with a positive rating from Cantor Fitzgerald. The coverage comes with a valuation that implies 459-percent upside. The ...

  • ACCESSWIRE6 days ago

    Today's Research Reports on Trending Tickers: Galmed Pharmaceuticals and Akcea Therapeutics

    The Nasdaq Composite Index shed 0.55 percent to close at 7,716.61. It’s unclear what it might do next, but it is clearly another step closer to a full-blown trade war,” according to David Carter, chief investment officer at Lenox Wealth Advisors. “If the trade skirmish escalates into a full-blown trade war, that will be a bigger force in the markets than the strong fundamentals,” Carter added.

  • This Is the Most Undervalued NASH Drug Stock, and Wall Street Is Ignoring It
    Motley Fool22 days ago

    This Is the Most Undervalued NASH Drug Stock, and Wall Street Is Ignoring It

    This NASH drug developer has a decent chance at beating all of its peers to market.

  • ACCESSWIRE23 days ago

    Upcoming FDA Catalyst and Disruptive Drug Candidate Indicate Big Near-Term Upside For This Unknown Healthcare Stock

    Dry Eye Syndrome is a huge market in the U.S., where Allergan's (AGN) Restasis has over $1.4 billion in sales annually. Investors haven't noticed, but a newly public Wize Pharma (WIZP) has an alternative drug that has been approved and used in parts of Europe for years. WIZP has U.S. rights to the drug and is running two clinical trials with results from the first to be released in the coming months.

  • Benzinga28 days ago

    Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 19) AngioDynamics, Inc. (NASDAQ: ANGO ) Array Biopharma Inc (NASDAQ: ...

  • PR Newswire28 days ago

    Galmed Pharmaceuticals Ltd. Announces Pricing of Public Offering of Ordinary Shares

    TEL AVIV, Israel, June 19, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, today announced that it has priced its previously announced underwritten public offering of 5,000,000 ordinary shares, at a public offering price of $15.00 per share. The gross proceeds to Galmed, before deducting the underwriting discounts and commissions and estimated offering expenses will be $75 million.   In addition, Galmed granted the underwriters a 30-day option to purchase up to an additional 750,000 ordinary shares at the public offering price, less the underwriting discounts and commissions.

  • PR Newswirelast month

    Galmed Pharmaceuticals Ltd. Announces Proposed Public Offering of Ordinary Shares

    TEL AVIV, Israel, June 18, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, today announced that it intends to offer and sell, subject to market and other conditions, ordinary shares in an underwritten public offering to raise aggregate proceeds of approximately $75,000,000. In addition, Galmed intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares sold in the offering, at the public offering price, less the underwriting discounts and commissions. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Foollast month

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can the momentum continue for these red-hot biotech stocks?

  • Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals
    Zackslast month

    Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals

    Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.

  • 3 NASH Stocks That Could Soar in the Second Half of 2018
    Motley Foollast month

    3 NASH Stocks That Could Soar in the Second Half of 2018

    The first treatments for this growing epidemic of liver disease will be huge blockbusters, and one of these biotechs could have what it takes.

  • ACCESSWIRElast month

    Hacking the Human Brain: This Unknown Stock (With 1 Very Prominent Shareholder) Could Change The Game & Make Shareholders Unheard of Returns

    NEW YORK, NY / ACCESSWIRE / June 15, 2018 / Elon Musk is investing millions in technology to enhance and connect the brain to robots and prosthetics. Upstart NeuroOne Medical (NMTC) could change that with their first FDA approved device, anticipated by the end of this year - a thin-film electrode that was pioneered at The Mayo Clinic. This prestigious institute owns 10% of NMTC, validating the tech.

  • Why Viking Therapeutics Stock Rose on June 13
    Market Realistlast month

    Why Viking Therapeutics Stock Rose on June 13

    On June 13, Viking Therapeutics (VKTX) stock rose ~9.1%, triggered by positive mid-stage trial results for peer Galmed Pharmaceuticals’ (GLMD) NASH (non-alcoholic steatohepatitis) drug, Aramchol. For more on the development, read Why Galmed Pharmaceuticals Stock Rose 151% on June 12. Galmed’s positive study results buoyed investors’ hopes of success for Viking Therapeutics’ NASH candidate, VK2809, which is in mid-stage trials and has a similar mechanism of action. On June 13, the SPDR S&P Biotech ETF (XBI) rose ~0.26%.

  • Are These Red-Hot NASH Stocks Still a Buy?
    Motley Foollast month

    Are These Red-Hot NASH Stocks Still a Buy?

    Investors are piling into NASH stocks right now, but which ones are the best long-term buys?

  • NASH Space in Focus as Galmed (GLMD) Posts Positive Data
    Zackslast month

    NASH Space in Focus as Galmed (GLMD) Posts Positive Data

    Investor focus is back on the NASH space as quite a few companies release promising data on their NASH candidates of late.

  • Galmed (GLMD) Soars on Positive NASH Data on Aramchol
    Zackslast month

    Galmed (GLMD) Soars on Positive NASH Data on Aramchol

    Shares of Galmed Pharmaceuticals (GLMD) surges significantly following positive top-line results on lead candidate Aramchol in NASH patients.

  • ACCESSWIRElast month

    Comprehensive Research Report, Galmed Pharmaceuticals Soars on Clinical Trial Results in Liver Disease Study

    NEW YORK, NY / ACCESSWIRE / June 13, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Galmed Pharmaceuticals Ltd. (GLMD), a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. On June 12, 2018, the company announced that a phase 2b trial of its ARREST study for the treatment of non-alcoholic steato-hepatitis achieved the endpoints necessary to support a phase 3 trial and a Food and Drug Administration marketing application. NASH is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally.

  • Why Galmed Pharmaceuticals Stock Rose 151% on June 12
    Market Realistlast month

    Why Galmed Pharmaceuticals Stock Rose 151% on June 12

    Galmed Pharmaceuticals (GLMD) stock rose 151.3% on June 12. Galmed stock rose after the company announced top-line results from the global 52-week phase 2b ARREST trial. The company is conducting the phase 2b ARREST trial to evaluate the safety and efficacy of its Aramchol for the treatment of individuals with non-alcoholic steatohepatitis (or NASH).

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: Sage Therapeutics and Galmed Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / June 13, 2018 / It was an exciting day for biotech stocks Sage Therapeutics and Galmed Pharmaceuticals. Sage rose higher after announcing that the FDA has allowed expedited development on its major depressive drug. Shares of Galmed soared to a new high after announcing positive results from its Phase 2b ARREST study.

  • Why Galmed Pharmaceuticals Ltd Stock Is Going Gangbusters Today
    InvestorPlacelast month

    Why Galmed Pharmaceuticals Ltd Stock Is Going Gangbusters Today

    This study was seeking to determine the effectiveness of using Aramchol to treat non-alcoholic steatohepatitis. Galmed Pharmaceuticals Ltd’s Phase 2b ARREST study saw the company splitting up 247 patients with biopsy-proven NASH that were overweigh or obese into three groups. The second took 400mg of the drug and the third was the placebo group.

  • Barrons.comlast month

    Galmed's 200% Jump Leads Biotechs Higher

    Galmed shot up 204% to $21.33 in morning trading, following positive data about its treatment for liver disease nonalcoholic steatohepatitis (NASH). Jefferies' Michael Yee writes that while Galmed's study formally missed statistical significance on both of its regulatory endpoints, "the trial did show significant trends that could hit significance in a larger trial." Given Galmed's size, he notes that Intercept Pharmaceuticals (ICPT) and Gilead Sciences (GILD), both of which have NASH data due out within the next year, could be another way to play the trend, as he anticipates both moving higher on the data.  The rest of the sector wasn't doing as well, but was generally higher: The iShares Nasdaq Biotechnology ETF (IBB) is up 0.4% to $110.37, and the SPDR S&P Biotech ETF (XBI) is 0.8% higher to $96.70.

  • Why Galmed Pharmaceuticals Ltd. Stock Is Skyrocketing Today
    Motley Foollast month

    Why Galmed Pharmaceuticals Ltd. Stock Is Skyrocketing Today

    Investors are cheering Galmed's experimental NASH drug, causing the biotech's shares to more than triple in value.